Armata Pharmaceuticals Enhances Patent Portfolio for Innovative Bacteriophage Therapies in the US #United_States #Los_Angeles #Armata_Pharmaceuticals #Patents #bacteriophage

Armata Pharmaceuticals Enhances Patent Portfolio for Innovative Bacteriophage Therapies in the US #United_States #Los_Angeles #Armata_Pharmaceuticals #Patents #bacteriophage
Armata Pharmaceuticals Secures $3.7 Million for Phase 3 Development of Antibiotic-Resistant Therapy #USA #Los_Angeles #Armata_Pharmaceuticals #AP-SA02 #antimicrobial_therapy
Armata Pharmaceuticals to Share Insights on Genetic Diversity of AP-SA02 at ISSSI 2026 #United_States #Los_Angeles #Armata_Pharmaceuticals #AP-SA02 #Staphylococcus_aureus
Armata Pharmaceuticals Achieves FDA Breakthrough Therapy Designation for Innovative AP-SA02 Treatment #United_States #Los_Angeles #Armata_Pharmaceuticals #FDA_Breakthrough #AP-SA02
Armata Pharmaceuticals to Present Breakthrough Bacteriophage Research at Major Investment Conference #United_States #New_York #Armata_Pharmaceuticals #Investment_Conference #bacteriophage
Exploring Armata Pharmaceuticals' Latest Insights on Phage Biology for Antibacterial Development #USA #Los_Angeles #biotechnology #phage_therapy #Armata_Pharmaceuticals